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Abstract
Among the transmissible spongiform encephalopathies (TSEs), chronic wasting 
disease (CWD) in cervids is now the rising concern within Europe. CWD will be 
outlined in this chapter gathering its epidemiology, transmission, diagnosis, genet-
ics, and control. Prion diseases are fatal neurodegenerative diseases characterized 
by the accumulation of an abnormal isoform of the prion protein (PrPc), usually 
designated by PrPsc or prion. CWD is a prion disease of natural transmission affect-
ing cervids detected mainly in North America. The first European case was detected 
in Norway, in 2016, in a wild reindeer; until April 2018, a total of 23 cases were 
described. The definite diagnosis is postmortem, performed in target areas of the 
brain and lymph nodes. Samples are first screened using a rapid test and, if positive, 
confirmed by immunohistochemistry and Western immunoblotting. It is not pos-
sible to establish a culling plan based on the genotype, once affected animals appear 
with all genotypes. However, some polymorphisms seem to result in longer incuba-
tion periods or confer a reduced risk. The control is not easy in captive cervids and 
even more in the wildlife; some recommendations have been proposed in order to 
understand the danger and impact of CWD on animal and public health.
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1. Introduction
The study and monitoring of wildlife diseases are key points for establishing 
conservational policies for wild fauna.
Wildlife are often in double risk from disease due to the high number of infec-
tious diseases of wildlife origin that affects humans and (or) domestic animals and 
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also the opposite, humans and domestic animals’ diseases that could affect the wild-
life. Likewise, due to habitat changes, the introduction of pathogens from domestic 
animals as well as other actions with long-term adverse effects for the conservation 
of species needs to have supervising.
As in other diseases, some wildlife animal species could be at risk for transmis-
sible spongiform encephalopathies (TSEs), acting as a potential prion reservoir, 
threatening the livestock and public health.
TSEs are fatal neurodegenerative diseases characterized by the accumulation of 
an abnormal isoform, partially resistant to the enzymatic digestion, of the cellular 
prion protein (PrPc), usually designated by PrPsc or prion. Due to its conforma-
tional arrangement, it is very resistant to common inactivation procedures used on 
conventional infectious agents. As PrPc is host-encoded by the PRNP gene, poly-
morphisms in this gene can act upon the susceptibility or the resistance to TSEs.
The most common and well-known diseases of this group are scrapie in small 
ruminants, bovine spongiform encephalopathy (BSE), Creutzfeldt-Jakob disease 
(CJD) in humans, and chronic wasting disease (CWD) in cervids.
Scrapie and CWD are recognized as natural transmitted TSEs, so wildlife can be 
naturally affected by these two TSEs.
Since scrapie was identified in mouflon sheep (Ovis musimon) [1], wild spe-
cies of sheep and goats, like Iberian wild goat (Capra pyrenaica), and Pyrenean 
chamois (Rupicapra P. pyrenaica) can also be infected by scrapie as well as by 
BSE. Furthermore, according to some studies, European wild ruminants have a 
PRNP genetic background that is compatible with TSE susceptibility [2, 3].
Albeit limited, some countries, namely, Estonia, Finland, Spain, and Cyprus, 
reported negative results on samples tested for TSE in other wild animal species—
mink (Mustela lutreola), fox (genus Vulpes), raccoon dog (Nyctereutes procyonoides), 
bison (Bison bison), and Cyprus mouflon (Ovis gmelini ophion) [4].
Considering that CWD is a TSE affecting several cervid species, a very conta-
gious disease with an efficient horizontal transmission, appearing to be enzootic 
and to be expanding both geographically and in prevalence [5], all the sections in 
this chapter are focused in order to better characterize the epidemiology, transmis-
sion, pathogenesis, diagnosis, genetics, and control of this disease.
2. Molecular basis of transmissible spongiform encephalopathies (TSEs)
2.1 Biology of the etiologic agent
Initially, TSEs were thought to be caused by “slow viruses” (reviewed in [6]). 
However, as the agent causing scrapie was not deactivated by both chemical and 
physical procedures, which modify or destroy nucleic acids, it was suggested that 
this infectious agent was not harboring nucleic acids. Thus, in 1967 Griffith pro-
posed a model in which the scrapie agent could be a protein, but it was Prusiner 
in 1982, after confirming that procedures used to modify or destroy proteins 
deactivated the scrapie agent, who published that the etiologic agents of TSEs were 
proteinaceous infectious particles, called prions [6, 7].
According to this protein-only hypothesis, TSEs are caused by the conversion 
of the physiological cellular prion protein (PrPc) into a pathogenic misfolded 
isoform (designated PrPsc) that is able to propagate by recruiting and transform-
ing more PrPc, by an increase in β-sheet structure and a propensity to aggregate 
into oligomers (reviewed [6, 8]). Moreover, this conformational change confers 
to PrPsc a greater insolubility in nonionic detergents, high resistance to heat and 
chemical sterilization, and partial resistance to protease digestion—the truncated 
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PrP 27–30 kDa (reviewed in [8–10]). Until now, this latter feature has been used for 
diagnostic purposes, being PrPsc a diagnostic marker for these diseases (see Section 
6 Diagnosis of CWD, in this chapter).
PrPc is host-encoded by the PRNP gene (see Section 2.3. Prion protein gene, 
in this chapter) and is normally present in the cell surface in different organs 
and tissues of mammals and other vertebrates but with high expression levels in 
the central and peripheral nervous systems. It is a glycosylphosphatidylinositol 
(GPI)-anchored glycoprotein of 33–35 kDa with a C-terminal globular domain, 
an N-terminal flexible tail, a single disulfide bond, and an α-helix content. 
The N-terminal tail includes two charged clusters, the octarepeat region and a 
hydrophobic domain. At the C-terminus, in the globular domain upstream of the 
sialylated GPI anchor, there are two N-glycosylation sites [11]. Thus, PrPc has two 
putative sites of glycosylation, and three glycoforms of PrP can be described: di-, 
mono-, and non-glycosilated PrP. The relative proportions of these glycoforms and 
the size of the unglycosylated PrPsc fragment are dependent on the strain of prion 
(reviewed in [12]).
Regarding the physiological function of the PrPc, it has not been clarified yet; 
nevertheless, there are several proposed roles; ones are supported by compatible 
results of different experiments (neuronal excitability; glutamate receptor func-
tion, neurite outgrowth; neuroprotection; copper, zinc, iron, and lactate metabo-
lism; and peripheral myelin maintenance), while others are yielding inconsistent 
results (synaptic transmission and plasticity, memory formation, stabilization of 
sleep and circadian rhythm, calcium homeostasis, and toxicity elicited by oligo-
meric species) [11].
While the structure of PrPc is well studied and identified, the structure of PrPsc, 
the mechanism by which PrPc converts into PrPsc in a posttranslational process, and 
the molecular mechanisms behind prion strains are still not known, despite all the 
experimental attempts [8–10].
PrPsc, as a physical template, compels PrPc, with the same primary but different 
secondary, tertiary, and quaternary structures, to adopt the PrPsc conformation, 
probably on a complete unfolding of PrPc, followed by refolding. To thoroughly 
comprehend this molecular process, it is essential to know the architecture of PrPsc. 
As extensively reviewed by Requena and Wille [9, 10], distinct molecular models 
have been proposed for PrPsc (27–30 kDa): (1) a four-stranded β-sheet plus two 
C-terminal α-helices [13, 14]; (2) an antiparallel, intertwined β-helix structure 
[15]; (3) a parallel β-helix [16]; (4) a fold modeled on the human TATA-box-binding 
protein containing a five-stranded β-sheet, with the C-terminal α-helices [17];  
(5) a “spiral model” with three α-helices of the original structure and four β-strands 
[18]; (6) a unit consisting of a left-handed four-rung parallel β-helical fold for 
the N-terminal part and α-helical state for the C-terminal portion, assembled as a 
trimer [19]; (7) a PrP primary structure based onto the β-helical template and the 
C-terminal α-helices [20]; (8) a β-helical architecture with a threefold domain in the 
trimeric unit and α-helical structure for the C-terminal portion [21]; (9) a two-rung 
β-helix with the C-terminal α-helices [22]; (10) a parallel in-register intermolecular 
β-sheet (PIRIBS) architecture [23, 24]; and (11) a parallel β-helix extended to the 
C-terminal portion of the PrP molecule [25].
Nevertheless, none of these models have explained all the experimental results. 
Recently, methodologies like cryo-electron microscopy and X-ray fiber diffraction 
have pointed out a four-rung β-solenoid as the basic structural element structure of 
PrPsc [26], though the available structural information is still limited to determine 
the PrPsc architecture in atomic details (reviewed in [10]).
To explain strain diversity of prions, the prion-only hypothesis considers that, 
in the absence of a nucleic acid, the variety of PrPsc conformers and its mixture 
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may result in different prion strains. Each prion strain presents a specific disease 
phenotype (incubation times, clinical signs, histopathological lesions, PrPsc deposi-
tion patterns in the brain, and PrPsc biochemical characteristics) which is exactly 
preserved upon serial passage within the same host genotype. Nevertheless, the 
molecular mechanisms by which a range of PrPsc conformers would be produced 
and selected have not been yet established (reviewed in [8]).
In relation to chronic wasting disease (CWD) prion strains, two prevalent CWD 
prion strains (CWD1 and CWD2) were identified in North America based on 
transmission in transgenic cervid (TgCerPrP) mice of several CWD isolates from 
different cervid species and geographic areas. CWD1 and CWD2 showed distinct 
incubation time, clinical signs, and neuropathologic profile but with indistinguish-
able electrophoretic migration patterns of di-, mono-, and non-glycosyl forms of 
PrPsc [27], reviewed in [28]. These bioassay results showed that elk may be infected 
with either CWD1 or CWD2 strains, while in deer CWD1/CWD2 strain mixture 
can be present ([27], reviewed in [28]) (Figure 1).
Regarding the CWD prion strain(s) responsible for the outbreaks of the disease 
in new geographic areas—South Korea, Norway, and Finland—the available data is 
still limited. The strain characterization of the Korean CWD cases in elk in 2001 and 
2004 suggested a single strain responsible for the outbreaks imported from Canada 
[29], without identifying if it was CWD1, CWD2, or both. The biochemical analysis 
and immunohistochemistry (IHC) distribution of PrPsc from Norway reindeer 
revealed a pattern indistinguishable from North America isolates [30]. Remarkably, 
in CWD-affected moose in Norway, a different phenotype was observed in both 
PrPsc distribution and biochemical features, suggesting a presence of a different 
type of CWD prion strain in moose from this country (designated Nor-16CWD) 
[31] (Figure 1).
Novel cervid prion strains have been experimentally generated by adaptation 
of prions from other species, for instance, scrapie (SSBP1, an American classical 
scrapie isolate) [28] and BSE [32], demonstrating that cervid species can also be 
susceptible to other prions. Moreover, CWD prions easily adapt to new species (see 
Section 4), including sheep, cattle, and squirrel monkeys. Thus, there is a putative 
risk of development of novel CWD-related prion disease in livestock by grazing in 
CWD-contaminated pasture (Figure 1). Lastly, the ability of the CWD prions to 
cross the human species barrier has to be further evaluated, but amino acid residues 
(residues 165–175) in the β2–α2 loop sequence of human PrPc can constitute a spe-
cies barrier to its conversion by CWD prions [33], reviewed in [28].
2.2 Prions and the deviations in the central dogma of molecular biology
According to the central dogma of molecular biology, first published in 1958 
and revisited later [34], heritable information is stored in DNA, expressed as RNA, 
and translated into protein. Nevertheless, this paradigm has been updated by many 
aspects of the regulation of gene expression, namely, by the identification and char-
acterization of alternative splicing, alternative promoters, alternative polyadenyl-
ation events, and the increasing number of noncoding RNAs (ncRNAs) with critical 
importance in the regulation of messenger RNA (mRNA) [35] and the discovery of 
“prions”: prion proteins can adopt multiple conformations, at least one of which has 
the capacity to self-template [36, 37] (Figure 2).
2.3 Prion protein gene (PRNP)
The astounding improvement in genetic tools and bioinformatic programs/
algorithms and the incredible amount of data deposited freely in the main scientific 
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databases allow us to use comparative genomics in an effective manner. Figure 3  
contains the representation of the PRNP gene in Homo sapiens, used as a refer-
ence and establishing a comparison with other animal species according to the 
Ensembl database. This gene is constituted by two exons, although a single exon 
is responsible for the open reading frame (ORF) and the remaining sequence 
contains untranslated and regulatory regions. Some animal species have the same 
distribution, while others contain a single exon (e.g., Canis lupus familiaris, Felis 
catus, and Ovis aries), three exons (Cervus elaphus and Odocoileus virginianus from 
Cervidae family), or four exons (like Bos taurus), according to Ensembl database. 
Nevertheless, a high level of conservation at the coding sequence and correspond-
ing protein sequence is maintained (as confirmed in Figure 4).
The fundamental event in the pathogenesis of TSE is not a primary structure 
modification but the conversion of the normal cellular prion protein (PrPc) into 
the misfolded pathogenic isoform (PrPsc) [38]. In fact, PrPc and PrPsc share the 
same amino acid sequence, but differences in the secondary structure originate the 
tertiary and quaternary structures that dictate the PrPsc with new physicochemical 
properties, namely, insolubility in nondenaturing detergents and partial resistance 
to proteolysis. It is therefore important to identify the specific codons and amino 
acids with relevant importance in the protein structure dynamics.
Rongyan and collaborators [39] compared the PRNP gene sequences among 83 
species and reinforced a remarkable degree of conservation among the mammalian 
sequences. In order to confirm this statement, a DNA, RNA, and protein compari-
son of PRNP among humans, bovine, ovine, caprine, and deer was performed. 
According to this comparison, human PRNP is less similar compared to the oth-
ers, which is understandable since they are phylogenetically more distant species. 
However, the protein comparison showed a high similarity between all these species 
(above 90%), indicating a high conservation of PrP.
In order to add supplementary information especially regarding wild species, the 
PrP protein sequences from 13 different species were compared and are presented in 
Figure 1. 
Summary of CWD prions and transmission. Like North America-CWD-isolates with PrPres biochemical and 
PrPres distribution similar to that described in North America CWD cases.  natural transmission;  
putative transmission;  experimental transmission;  potential spread of CWD prions or decrease of PrPres 




Figure 4. The high level of conservation suggests the preservation of some impor-
tant functional characteristics of PrP through evolution.
According to NCBI-SNP database (accessed in December 2018), 3683 variations 
in the human PRNP gene were presented. Some of these variations are located in 
the coding sequence and originate modifications in the protein. Once PrP is highly 
conserved, the variations already described in humans can be used to predict varia-
tions in other species. In order to simplify this process, all the missense and non-
sense mutations associated with prion diseases described in humans are presented in 
Figure 2.
Variations in PrP sequences exist between species and also between individu-
als of the same species. It was already demonstrated that this fact can influence 
the susceptibility to prion infection and ultimately to disease. Chronic wasting 
disease appear to have a higher potential of transmissibility than other forms 
of prion disease, and it has been confirmed that some genetic variations are 
associated with lower rates of infection and slower progression of clinical mani-
festations [40]. A total of 17 polymorphic sites have been reported in the PrP in 
Cervidae species.
Historically, O’Rourke and collaborators [41] were the first authors that 
reported that PRNP gene from Cervus elaphus was polymorphic at codon 132 
encoding methionine (M) or leucine (L). This codon is equivalent to codon 129 in 
Figure 2. 
Updated vision of the classical central dogma of the molecular biology. A DNA sequence can originate multiple 
RNAs (by using different promoters, by alternative polyadenylation and alternative splicing events). Some 
of these RNAs can be degraded by nonsense mediated decay (NMD), normally if they contain a premature 
termination codon (PTC). Other RNAs are not translated but still have a possible regulatory function 
(noncoding RNAs, ncRNA) and supplementary RNAs are translated originating a different protein, with similar 
or unrelated function comparing to the canonical protein. The prion postulation assumes that an abnormal 
protein conformation (PrPsc) propagates itself via an autocatalytic mode by recruiting the normal cellular 
isoform (PrPc) as a substrate and acting as the disease transmissible agent. This misfolding can be reversible and 
prion proteins have the ability to interact with nucleic acids (DNA and RNA) and other polyanions (as lipids).
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Figure 3. 
Organization of the Homo sapiens PRNP gene. From the two exons, only exon 2 is codifying for the PrP protein 
(black square). The coding sequence is presented below with the top lines showing the nucleotide sequence and 
the bottom lines showing the amino acid sequence. Missense and nonsense mutations in PrP associated with 
human prion diseases are marked in red. Information retrieved from Ensembl and NCBI databases were used 
to create this scheme.
the human protein encoding either M or valine (V) [42]. According to Collinge 
and colleagues [43] and Palmer and collaborators [44], this variation has an 
important impact on human prion disease presentation. In the same direction, 
regarding CWD, O’Rourke and collaborators [45, 46] indicated that the L132 
allele protected against this disease in Cervidae. Although all PRNP genotypes 
can be affected with CWD, there are some polymorphisms that appear to result in 
longer incubation periods in some species. The polymorphisms Q95H and G96S 
are related to the reduction of the risk of infection [47]. S96S or G96S and G95H 
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seem to produce a reduced susceptibility, with longer survivor period [48], being 
underrepresented in CWD-affected populations [45]. Regarding S225F poly-
morphism there is a differential susceptibility to experimental oral exposure and 
incubation periods [45, 49].
Table 1 presents the information concerning the amino acidic variations 
reported until 2018, with the references and functional implications in the suscepti-
bility to CWD.
3. Epidemiology of chronic wasting disease (CWD)
3.1 Natural history and geographical distribution of CWD
Descriptions of CWD date back to 1967, in which a body-wasting syndrome 
associated with behavioral changes was described in Colorado in a closed herd 
of captive mule deer. However, only a few years later, in 1980, the patholo-
gists Elizabeth Williams and Stewart Young observed histological lesions that 
made it possible to identify the disease as transmissible spongiform encepha-
lopathy, in deer from wildlife research facilities in Colorado and Wyoming. 
These lesions included neuropil spongiform transformation, intracytoplasmic 
vacuoles in neuronal perikaryons, and significant astrocytic hyperplasia and 
hypertrophy [60].
Figure 4. 
Alignment of PrP protein sequences among 13 different species. T-coffee was the multiple alignment tool 
used from EMBL-EBI (https://www.ebi.ac.uk/Tools/msa/tcoffee/) and Genedoc version 2.7.000 was 
the multiple sequence alignment editor. The accession numbers of each species considering a short name 
(by order of presentation in the alignment) are: Hs_ENSP00000368752.4; Bt_ENSBTAP00000043233.2; 
Oa_ENSOARP00000004991.1; Ch_ NP_001301176; Rr_UniProt_spQ5XVM4; Cc_AY639096; Ce_UniProt_
spP67987; Cn_UniProt_trQ6DN38; Ov_UniProt_trQ7JIQ1; Oh_UniProt_trQ6VS46; Aa_UniProt_trQ693S2; 
Rtg_UniProt_trQ3Y673; Dd_UniProt_trQ7YSF3. Besides human (the reference), the four following species 
belong to Bovidae family and the last eight species belong to Cervidae family (highlighted with a rectangle 
frame). The arrows locate the seventeen polymorphic amino acids described in Cervidae.
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In 1991, amyloid plaques reactive to antibodies produced against scrapie were 
identified in the cerebral gray and white matter and in molecular, pyramidal, and 
granular layers of the cerebellum of infected captive mule deer (Odocoileus hemionus 
hemionus) [61]. In the same year, a similar study identified scrapie amyloid-immu-
noreactive plaques in Rocky Mountain elk (Cervus elaphus nelsoni) and hybrids of 
mule deer and white-tailed deer (WTD) (Odocoileus virginianus) [62].
After its first identification, CWD was detected in a mule deer from Wyoming, 
and, until 1980, they had already identified 53 cases in mule deer (Odocoileus hemio-
nus hemionus) and 1 case in a black-tailed deer (Odocoileus hemionus columbianus) 
from wildlife facilities in Colorado and Wyoming [60].
The disease continued to be detected in new cervid species as Rocky Mountain elk 
(Cervus elaphus nelsoni) in Colorado and Wyoming wildlife facilities [63]. Subsequently, 
the disease was identified in free-ranging animals: mule deer and elk in the same states 
[64] and white-tailed deer in Nebraska and South Dakota in 2001 [65, 66].
The limited area of southern Wyoming, Northern Colorado, and Western 
Nebraska has been considered the endemic area. This area spreads rapidly, and new 
epidemic outbreaks were identified in other states including areas not contiguous 
geographically to endemic areas [66].
The establishment of disease surveillance and detection programs in both wild 
and captive cervids contributes to the knowledge of the geographical distribution of 
the disease [67]. However, the lack of well-defined limits of the affected areas, the 
low incidence, and the insufficient sampling could lead to underestimated preva-
lence rates [66].
a.a Position Consensus a.a Variation Reference
2 V M [50]
20 D G [51, 52]
59 G S [3, 52]
95 Q H [40, 52, 53]
96 G S [52, 53]
98 T A [3]
100 S N [54]
116 A G [52]
129 G S [55]
132 M L [45, 56, 57]
138 S N [55]
168 P S [3]
169 V M [55]
209 M I [50]
225 S F [58]
226 Q E/K [3, 52, 58, 59]
230 Q L [52]
The position considers the Cervidae prion protein. Legend: amino acid codes—A, alanine; D, aspartic acid; E, glutamic 
acid; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, asparagine; P, 
proline; Q , glutamine; R, arginine; S, serine; T, threonine; V, valine.
Table 1. 
Amino acid variations and susceptibility to CWD.
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At present, the disease has been identified in captive and free-ranging cervids in 
24 states of the United States of America (USA) [68]. Considering only free-ranging 
cervids, CWD was identified in 270 counties in 24 states, according to March 2019 
data, namely, Arkansas, Colorado, Illinois, Iowa, Kansas, Maryland, Michigan, 
Minnesota, Mississippi, Missouri, Montana, Nebraska, New Mexico, New York, 
North Dakota, Pennsylvania, South Dakota, Tennessee, Texas, Utah, Virginia, West 
Virginia, Wisconsin, and Wyoming [69, 70].
In Canada, the first case was detected in 1996 in Saskatchewan, in a captive 
elk [71]. The second case was diagnosed in 1998 in a farmed elk and the third 
case, in 2001, in a captive 24-month-old Rocky Mountain elk. In this herd, no 
other cases had been detected; however, an animal which died 2 years earlier 
without postmorten examination had been introduced previously from an 
infected herd [72]. In 2002, the first case was identified in farmed white-tailed 
deer [71]. Nevertheless, considering a retrospective study done in Toronto 
Zoo cervids that died between 1973 and 2003, CWD exists in Canada since the 
1980s. CWD infection was detected in seven mule deer and one black-tailed 
deer [73].
According to the Canadian Food Inspection Agency, data about cervid herds 
infected with CWD are reported since 1996 [69]. In 2001, CWD was identified in 
21 herds, the highest number between 1996 and 2018. Until last year, the disease 
was circumscribed to two provinces: Alberta and Saskatchewan [72]. A screening 
for CWD in caribou (Rangifer tarandus) in northern Quebec revealed no positive 
animals [74]. However, data from 2018 reported the disease in Quebec in a red deer 
herd [69, 70, 75].
Recent data, from 2018 official reports, describe CWD in captive elks (in the 
province of Alberta and Saskatchewan), white-tailed deer (in Saskatchewan), 
and red deer (in Quebec and Saskatchewan) [69, 75]. CWD was also identified in 
free-ranging cervid populations in Canadian Alberta and Saskatchewan provinces 
[69, 71, 75].
The first case outside North America was detected in 2002, in South Korea, 
associated with a 7-year-old elk imported from Canada [76].
CWD was first recognized in Europe in March 2016 in a free-ranging female 
reindeer (Rangifer tarandus) in the Nordfjella mountain range of Southern Norway 
[30]. Since then, Norway further intensified its monitoring by sampling with the 
aid of hunters and governmental culling. A total of 41,125 cervids had been tested 
leading to the detection of CWD in 19 wild reindeers (Rangifer tarandus), 3 wild 
moose (Alces alces alces), and 1 red deer (Cervus elaphus) [77, 78]. In Finland, one 
CWD-affected moose was detected in 2500 cervids tested [78].
3.2 Host range of CWD
CWD has been identified in several members of the family Cervidae: white-
tailed deer (Odocoileus virginianus) [79], mule deer (Odocoileus hemionus) [60], 
Rocky Mountain elk (Cervus elaphus nelsoni) [80], moose (Alces alces shirasi) [81], 
reindeer (Rangifer tarandus) [30], moose or Eurasian/European elk (Alces alces 
alces), and red deer (Cervus elaphus) [77].
There are other animals that can experimentally be infected, both cervid and 
noncervid species. The experimental host range includes squirrel monkey [82, 83], 
several species of voles [84, 85], white-footed mice [29], Syrian golden hamsters 
[86], ferrets [87], raccoons [88], cats [89], pigs [90], and sheep [91]. Other cervids 
are susceptible to experimental CWD infection: fallow deer (Dama dama) [92] and 
muntjac deer (Muntiacus reevesi) [93]. However, CWD was not yet detected natu-
rally in these species.
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3.3 Prevalence and dissemination of CWD
The prevalence of the CWD is quite different in wild or captive cervids. In 
free-ranging cervids, the disease spreads slowly, often with a stable prevalence and 
low diffusion rate [94]. However, CWD prevalence in wild cervids and geographi-
cal areas with animals infected are increasing every year. Prevalence could reach 
31% in hunting deer from Wyoming (USA) [95] and exceed 10% in elk from Rocky 
Mountain National Park [96]. In Europe, the prevalence in cervids in Norway is 
0.05% (23 in 41,125 cervids) and 0.04% in Finland (1 in 2500 cervids), which 
is very low, but it is expected to increase, as it is a very contagious form of TSE, 
endemic, and difficult to eradicate [78].
In captive cervids the prevalence is higher and may reach 79% or more of 
affected animals on the herd. In young animals, this number could be even higher 
[66, 97]. The annual incidence may be higher than 50% in white-tailed deer and 
mule deer [95].
The diffusion of CWD, despite the many studies existent, is not well under-
stood. The disease spreads slowly, in free-ranging cervids, probably following river 
corridors or associated with the movements of males, as proposed for white-tailed 
deer (Odocoileus virginianus) [98]. However, there are no definite conclusions 
about the origin of the disease in wild cervids. CWD foci in these animals could be 
extensions of the initial endemic focus, secondary foci, or they could correspond 
to the spontaneous development of different foci of the disease [94]. In captive 
animals, CWD spread probably followed slightly different pathways. The occur-
rence of the disease and its irregular propagation with their appearance in two 
geographically distant endemic regions must be associated with the commercial-
ization of infected animals between the different herds. Occasionally the disease 
was detected simultaneously in herds and wild animals in the same region, previ-
ously or later, in wild animals suggesting a spillover of the infection from captive 
to free-ranging animals [94].
4. Transmission
Concerns about transmission between species of TSEs, and particularly trans-
mission of animal TSEs to humans, have existed since the infectious nature of these 
diseases was demonstrated, but there was no evidence of zoonotic transmission 
until the link between BSE and a new human TSE (variant CJD or vCJD) was estab-
lished in the late 1990s. Evidence for the transmission of BSE from cattle to humans 
came from a diversity of sources, combining careful surveillance and epidemiologi-
cal studies, often involving the development of new techniques and animal models. 
The demonstration of the zoonotic transmission of BSE also renewed concerns 
about the public health risks of other TSEs leading to enhanced surveillance and 
efforts to control scrapie and CWD [99].
Efficient control measures were applied for BSE and scrapie in cattle, sheep, and 
goats. However, CWD prions present a challenging risk, affecting both captive and 
wild cervids [100].
The experimental transmission of BSE in cervids and the bioassay in trans-
genic mice strongly support the claim that CWD agents are not related to classical 
BSE. However, the possible relationships between CWD and other TSE agents 
circulating in animal populations (transmissible mink encephalopathy (TME), 
scrapie) are still uncertain [99].
TSEs are horizontally transmitted by oral ingestion (kuru, BSE, vCJD, TME, 
feline spongiform encephalopathy (FSE), CWD), by environmental contact with 
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infectious prions (scrapie, CWD), by blood transfusion (vCJD, CWD, scrapie), or 
by iatrogenic exposure (vCJD, sCJD) [93]. Horizontal transmission of CWD also 
includes skin, oral, and nasal routes [101].
CWD prions can be discarded in urine, feces, saliva, blood, and velvet antler 
(clinical and preclinical stage of the infection) and can be found in skeletal muscle, 
fat, viscera, and the central nervous system [102, 103]. For this, there is a high risk 
of exposure to CWD prions, not only for cervids and other wild animals but also 
for hunters who may contact directly with infected animals and people consuming 
venison [104] (Figure 1).
Although still unclear, natural CWD transmission between animals has 
occurred. Environmental contamination and infectivity can persist in pastures for 
2 years after the death of animals affected with CWD, as shown by studies per-
formed in grazing presumably highly contaminated [49].
Both horizontal and environmental transmissions efficiently disseminate 
CWD. Decomposing carcasses and the placenta also contribute for this transmis-
sion as the prion agent is environmentally very stable persisting for many years 
where TSE-infected animals stood [94]. Other putative sources for CWD spread 
are predators/raptors and scavengers as prions remained infectious after passage 
through the digestive system of American crows [105, 106] and coyotes [107] which 
were orally infected with scrapie and CWD, respectively (Figure 1).
High infectivity and rapid transmission between cervids result in a high preva-
lence and can exceed 90% in captive animals [108] leading to the increased CWD 
exposure of humans and other animals, mainly by the consumption of prion-
infected animal products or grazing on prion-contaminated pastures, respectively. 
So, studies concerning the zoonotic risk of CWD and transmission to other animal 
species are very important with a high interest for public and animal health. The 
effect of the species barrier (lower transmission efficiency compared to that within 
the donor species) is very present while studying the interspecies transmission of 
CWD prions. Investigations identified a key influence of amino acid sequence dif-
ferences in the prion protein between species as well as a strong effect of the prion 
strain type [109, 110]. For prions, strain type is characterized by a set of properties 
that define infection and pathogenesis not explained by differences in amino acid 
sequence [111]. Both factors influence species interaction, dose, route of inocula-
tion, and age of the host [109, 110]. Furthermore, prion agents can adapt to a new 
host species, only becoming virulent after repeated passage [112].
For the study of CWD interspecies transmission, experimental inoculations 
were conducted mainly by intracerebral (IC) inoculation, resulting in a success-
ful transmission to ferrets (Mustela putorius furo) [113] but unsuccessful to Syrian 
golden hamsters (Mesocricetus auratus) even after multiple attempts [64]. The 
ferret-adapted CWD was, however, and after several passages, transmitted to ham-
sters, demonstrating that interspecies transmission can be altered by the adaptation 
to a new host [113]. The IC inoculation of mule deer CWD to goats presented an 
incubation period of about 6 years, a longer period when compared to what hap-
pens with scrapie [64, 114].
Transmission experiments of CWD prions from white-tailed deer, mule deer, 
and elk to transgenic mice expressing deer, elk, sheep, cattle, or human PrPc sug-
gest that the transmission barrier for CWD prions among different species of the 
cervid family is low, whereas the transmission barrier for CWD prions to sheep, 
cattle, and humans is high ([115–119], cited by [114]). Although still unclear, 
species barrier is thought to be controlled, at least in part, by the differences in 
the primary PrP sequences of donor and recipient animals [120–122] that affect 
the structure and folding of each prion protein ([123] cited by [114]). Studies of 
amino acid differences have demonstrated that there is a high level of conservation 
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of the prion protein between species (90%) being the energy barrier increased for 
conversion, when compared to others, with some major differences in the amino 
acid sequence [33].
Although the hypothesis that CWD is transmitted to humans is not supported 
(reviewed by [100]), results from in vitro experiments suggest that the species 
barrier is not absolute.
No correlation between CWD prion exposure and human prion disease was 
demonstrated by epidemiological studies, and humanized transgenic mice did not 
demonstrate transmission. CWD transmission to macaques has been unsuccessful 
to date, although squirrel monkeys seem to be susceptible to CWD prions [100].
The negative transmission results reported in seven studies support the conclu-
sion that the transmission barrier associated with the interaction of human PrP and 
CWD prions is fairly strong and is stronger than the species barrier between human 
PrP and the BSE prion ([124] cited by [100]).
It is hypothesized that, as a result of an extensive human exposure, a CWD prion 
strain able to be transmitted to humans can emerge, even with no current evidence 
that it can cause disease [125]. So there is a risk of exposure for those who directly 
contact with cervids or contaminated environment or who consume venison [104]. 
However, variation in CWD prion strains, human genetic heterogeneity, other fac-
tors contributing to individual variation, and some evidence that intraspecies and 
interspecies passage of CWD prions may increase the risk that CWD prions adapt 
to have a lower species barrier for transmission to humans, complicating this area of 
research [112].
Wild-type inbred strains of mice (e.g., RIII, C57BL, and VM) were important 
for the identification and characterization of different types of scrapie prions 
[126–131], but CWD transmission to wild-type mice presented only few results 
[29]. In order to optimize time and resources as well as the results obtained, when 
performing studies of scrapie prions, transgenic (Tg) mice for ovine or cervid prion 
protein gene were developed [115, 117, 118, 132–134].
According to several studies, cervidized mice have been established as appropri-
ate mouse bioassay models for the study of CWD. CWD prions were transmitted 
efficiently to TgElk mice with no evidence of transmission to ovinized mice—Tg338 
(transgenic mouse line expressing the ovine VRQ prion protein) [119].
There are currently no known cases of interspecies transmission of CWD prions 
to sheep or goats through natural exposure, and transmission resulting from direct 
inoculation has been relatively inefficient. Nevertheless, the potential for natural 
exposure of sheep and goats to CWD prions is presumably rising in parallel with 
the increasing incidence and geographic range of CWD [119]. In this study trans-
mission of classical scrapie and CWD prions from their native hosts to transgenic 
mouse lines expressing the ovine (Tg338) or cervid PrP was assessed. Inoculation 
of transgenic mice with scrapie prions from small ruminants or CWD prions from 
WTD (white-tailed deer) resulted in distinct transmission patterns. Scrapie prions 
transmitted efficiently to Tg338 but not to TgElk, whereas CWD prions from a 
natural host efficiently transmitted to TgElk but not Tg338. Unlike these distinct 
transmission patterns, efficient transmission of CWD prions following primary 
passage in sheep was observed in both Tg338 and TgElk mice. Experimentally 
transmitted CWD in small ruminants has been difficult to distinguish from natural 
cases of classical scrapie [119].
Peripheral lymphoid tissues may be a target for accumulation in cross-species 
transmission as observed with Tg338 mice intracerebrally inoculated with elk CWD 
prions with high rates in the spleen but low doses in the brain [110]. Transmission 
of CWD from mule deer or elk to sheep has been achieved following intracerebral 
inoculation [91, 135]. Yet, inoculation with brain homogenate from WTD with 
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CWD did not result in brain accumulation of PrPsc during primary passage in 
ovinized mice (Tg338). One factor that may have contributed to the lack of trans-
mission could be varying levels of PrPsc and PrPCWD between brain homogenates 
from animals with scrapie and CWD, respectively [119].
Non-Tg mice have been described as resistant to CWD infection [115], while the 
VM/Dk inbred strain of mice infected with wapiti CWD prions reported limited 
infection [29], suggesting the existence of some variable species barriers to the 
transmission of CWD [77].
Nalls et al. [93] have demonstrated mother-to-offspring transmission and 
disease progression to a viable cohort of offspring that were born to CWD-infected 
dams.
Several researchers noted that dissimilarity between PrP sequences alone does 
not accurately predict the transmissibility between species and other factors are 
under investigation. One that was used in recent studies was the conformational 
selection model, which proposes that compatibility between the three-dimensional 
molecular shapes of PrPsc and PrPc is more important than the sequences of the 
protein backbones [136].
5. Pathogenesis of CWD: the interaction of prions and immune system
The unique features of prions as infectious agents are also blatant when con-
sidering its interaction with the host’s immune system. As stated previously, PrPc 
is involved in important neurologic functions; however, the depletion of neuronal 
PrPc in experimental models, such as mice, cows, and goats, did not result in 
altered phenotypes [11]. This suggests the existence of redundant mechanisms 
that compensate the absence of PrPc, albeit its ubiquitous cellular expression. 
Pertaining the immune system, PrPc is expressed in lymphocytes, granulocytes, 
and stromal cells. This abundant expression may explain why PrPsc does not elicit 
specific immune responses despite its accumulation in high levels within the host’s 
secondary lymphoid tissues (SLT) in the initial phases of the infection. In par-
ticular, gut-associated lymphoid tissues (GALT), such as the Peyer’s patches in the 
small intestine, seem to be pivotal for the infection and disease process. As in most 
natural occurring prion diseases, CWD of cervids is acquired peripherally, mainly 
after oral exposure, after which prions replicate in GALT. The importance of 
GALT in the pathogenesis of prion diseases is well documented by several studies 
that revealed impaired neuroinvasion in the absence of Peyer’s patches [137–140].
5.1 M cells
Within GALT, studies suggest that prions depend on host M cells to enter the 
organism, as they seem to be involved in the initial transfer of the prion agent across 
the gut epithelium. These are specialized epithelial cells widely spread among the 
follicle-associated epithelium, which are involved in the transcytosis of particulate 
antigens and microorganisms from the gut lumen into the GALT [141]. M cells are 
essential to the gut immune system being fundamental to antigen recognition and 
presentation of pathogens or commensal microflora. As such, factors that increase 
M-cell density in the gut epithelium (coinfections or miscellaneous inflammatory 
conditions) may also increase susceptibility to orally acquired prion infections. 
A study by Wyckoff et al. [142] mentions the binding of prions to certain types 
of soil particles that may result in an increased uptake of prions from the gut 
lumen, but it is not yet clear if this uptake is mediated by M cells. Host infection by 
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M-cell-independent mechanisms cannot be disregarded, namely, those involving 
directly enterocytes from the follicle-associated epithelium [143] or other M-cell-
independent pathways [144].
5.2 Follicular dendritic cells (FDC) and B and T lymphocytes
Several studies show that in prion-infected hosts, high accumulations of 
disease-specific PrP are detectable within the B-cell follicles of the SLT [145–149]. 
After internalization, evidence suggests that prions accumulate and replicate in 
the follicular dendritic cells (FDC) that lie in the B-cell follicles and germinal 
centers of SLT [150–156]. FDC possess multiple slender and long dendritic pro-
cesses, differentiate from ubiquitous perivascular precursor cells (pericytes), 
and are a distinct lineage from bone marrow-derived conventional dendritic cells 
(DC) [157, 158]. FDC extend throughout the B-cell follicle being able to trap and 
retain large amounts of native antigens upon their surfaces in the form of immune 
complexes composed by antigen–antibody and/or opsonizing complement com-
ponents. Apparently, prions can be bound by opsonizing complement components 
[152–155], internalized, and replicated within FDC, as it was demonstrated that 
they accumulate upon PrPc-expressing FDC in the SLT of experimentally infected 
mice, sheep with natural scrapie, cervids with CWD, and patients with vCJD 
[145–149]. Subsequently, immunohistochemistry studies identified FDC as the 
first sites of prion conversion and replication in experimentally infected mice, in 
which increased prion labeling was observed on the plasma membranes of FDC in 
the Peyer’s patch germinal centers [143]. Furthermore, evidence suggests that FDC 
maturation and regression cycle are impaired by disease-associated prion protein, 
thus affecting immune function [159]. Despite this, some prion strains can establish 
infection within SLT regardless of FDC, as it was demonstrated by experimental 
studies in mice, where infection occurred associated to the high endothelial venules 
in the lymph nodes [160].
The role of B and T cells in prion disease pathogenesis remains uncertain. 
Experimental studies showed that mice lacking mature B and T cells were not 
susceptible to peripheral infection with prions [145, 161–163], despite prion disease 
pathogenesis being unaffected in T-deficient mice [162, 164, 165]; however, it seems 
that prions are not capable of replicating within B and T cells [166, 167]. These 
cells appear to be intermediary actors in prion diseases, by providing physical and 
humoral support to other cells, thus contributing to the homeostatic state of the 
immune system. However, B cells, in particular, seem to play a more active role 
during prion infection. The ability of secreting tumor necrosis factor-α (TNF-α) 
and lymphotoxins (LT) turns B cells pivotal in keeping FDC in their differentiated 
state, since in the absence of stimulation from these cytokines, FDC rapidly dedif-
ferentiate [168]. In Peyer’s patches, B cells migrate to the mesenteric lymph nodes 
and then return to the circulation [169]. It is this constant rotation between Peyer’s 
patches and SLT that may help B cells to disseminate prions acquired from FDC as 
they both migrate together through the germinal centers [170, 171]. Additionally, 
the accumulation of prions in the spleen and subsequent neuroinvasion are signifi-
cantly decreased in the specific absence of B cells [162]. It is also noteworthy that 
prions were detected in B cells from the blood of sheep with scrapie [172] and deer 
with CWD [173].
As it was already mentioned, FDC in the Peyer’s patches are major sites of early 
prion replication in orally infected animals, both experimentally [137–140, 174] 
and in the natural forms of the disease. The study of natural scrapie cases in sheep 
showed that GALT of the upper gastrointestinal tract exhibited early accumulation 
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of prions when compared to the large intestinal GALT, such as the cecal patches 
[175–178]. The rectoanal mucosa-associated lymphoid tissues (RAMALT), which 
also accumulate prion in naturally occurring cases of scrapie in sheep and goats, as 
well as in CWD in cervids, also displayed reduced incidence of prion accumulation 
at the earlier stages of disease [96, 179–184]. Taken together, these studies point out 
to the fact that prions first replicate within the GALT of the upper gastrointestinal 
tract and then spread to the local lymph nodes and to other SLT, such as the spleen. 
Additionally, it was observed that FDC in the spleen expressing PrPc were able 
to display high levels of prion replication that was impeded after PrPc expression 
blockage in these cells [185].
5.3 Mononuclear phagocytic cells
A heterogeneous population comprised of monocytes, conventional dendritic 
cells (DC), and macrophages seem to have also an important role in host infection. 
From a different lineage of the stromal-derived FDC, conventional DC [157, 158, 186], 
the antigen-presenting cells par excellence, are also involved in the transport of 
antigens both within Peyer’s patches and toward the mesenteric lymph nodes 
[187–189]. Their strategic position allows them not only to sample their local 
environment for pathogens and their antigens, processing them, but also to capture 
and retain unprocessed (native) antigens [190, 191]. Processed or native antigens 
are then delivered to B and T cells as DC undergo maturation and migrate toward 
the local SLT to initiate an immune response [190–193]. Prions are wrapped by DC 
either by complement opsonization, namely, by C1q and C3 components [155, 194],  
or in a non-specifically manner, through fluid-phase micropinocytosis [144]. 
Specific chemokines have been reported to play important roles in prion infec-
tions by regulating FDC and DC migration within the SLT. CXCL13 chemokine is 
expressed by FDC and other stromal cells in the B-cell follicles of SLT and recruits 
CXCR5-expressing cells toward them [195, 196]. On the other hand, CXCL13-
CXCR5 signaling mediates the migration of certain populations of DC toward 
the FDC-containing B-cell follicles [192, 193, 197], and studies have shown that 
the early accumulation of prions upon FDC in Peyer’s patches was impaired and 
disease susceptibility reduced, in the absence of CXCR5 expression by DC [198]. 
The interplay between FDC and DC during prion infection was also patent by the 
finding that early replication of prions upon FDC in the local SLT was inhibited 
when conventional DC were transiently depleted at the time of exposure [199–202]. 
Apparently, after being transferred across the gut epithelium either directly by 
enterocytes or by M cells, prions may be then internalized by DC [143, 199] and 
propagated by them toward FDC in Peyer’s patches [198]. The ability of DC to 
migrate into B-cell follicles [192, 193, 203] suggests that they may also propagate 
prions to and within SLT, namely, to the mesenteric lymph nodes.
Regardless of FDC and DC roles in the propagation of prions, there are other cell 
populations that appear to phagocytose and destroy them [204, 205]. In fact, it was 
observed that tingible body macrophages of the germinal centers display heavy PrPsc 
accumulations within their endosomal compartments during prion disease [143, 159, 
185]. It is speculated that macrophages may scavenge and degrade prions in an attempt 
to protect the host from infection, as it is suggested by studies that show that macro-
phage depletion resulted in an enhanced accumulation of PrPsc within SLT [206, 207].
5.4 Neuroinvasion
After being acquired orally, prions undergo replication and accumulation 
upon FDC, reaching a threshold above which neuroinvasion occurs. Experiments 
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in which immunohistochemical tracing was performed revealed that prions then 
infect enteric nerves and spread along efferent fibers of both the sympathetic 
(e.g., splanchnic nerve) and parasympathetic (e.g., vagus nerve) nervous systems, 
spreading within them to the CNS, where they ultimately cause neurodegeneration 
[143, 208–212]. The initial transfer of prions from FDC to the peripheral nerves 
continues surrounded by knowledge gaps, but it appears that tunneling nanotubes 
(TNT) may play an important role at this stage of the disease. These are slender 
membrane-bound cylinders of cytoplasm that connect cells to enable cell-to-cell 
communication and the intercellular transfer of plasma membrane or cytoplasmic 
components [213]. Since mononuclear phagocytes and DC are in close proximity 
with enteric nerves [214–217] and in vitro studies showed that prions can be trans-
ferred between DC and neurons via endolysosomal vesicles within TNT [215–218], 
it is possible that the same transfer also occurs in vivo. Another hypothesis is that 
the transfer of prions may also occur in association with small endosomal-derived 
vesicles, termed exosomes [219], as it was demonstrated experimentally. Studies 
supporting this theory are based on the observation that DC infected with prions 
can release exosomes that in turn may infect neighboring cells [220]. In the CNS, 
prion aggregates accumulate to a point where they overcome the structures within 
it, starting from the synapses and then proceeding to axons, where axonal retrac-
tion is observed, and then to the cell body, in which atrophy and neuronal loss are 
lastly observed [221–224]. The abovementioned process is, however, slowly and 
progressive, depending on factors such as prion agent strains, the existence of 
concurrent infections, and hosts’ age and immune status [144].
The onset of neurodegeneration is preceded by the activation of glial cells, 
microglia, and astrocytes [225, 226]. Microglial cells, in particular, by intervening in 
synaptic remodeling and in the removal of dead and dying cells, are important for 
the course of neurological changes during prion infection. Organotypic cerebellar 
culture devoid of microglia exhibited enhanced prion accumulation [227], whereas 
CNS prion disease pathogenesis was exacerbated in vivo in the absence of microglia 
[228]. Studies revealed that during prion infections, a cytokine response mediated 
by TGF-β and PGE2 develops within the CNS, stimulating microglia to adopt an 
anti-inflammatory status [223, 229, 230]. Evidence suggests that this anti-inflam-
matory ambiance may be beneficial for the host, as CNS prion infection in mice 
deficient in the anti-inflammatory cytokines interleukin (IL)-4, IL-10, and IL-13 
displays an aggravated disease pathogenesis [231, 232]. Other studies supported 
this hypothesis by the finding that blocking colony-stimulating factor (CSF) recep-
tor-1 resulted in the expression of selective anti-inflammatory microglial markers, 
slowing the development of neuropathology and extending survival times [233]. 
Activated microglia scavenge and clear prions and prion-affected cells, but neural 
degeneration seems to occur when prion accumulation is associated to an inflamma-
tory response in the microglia [234]. Together, these data point out to the existence 
of both anti-inflammatory and pro-inflammatory responses by microglial cells 
during CNS prion infections [226, 234] contributing to the symptoms of this disease.
6. Diagnosis of CWD
Classification of CWD as TSE required histopathological examination of brains 
from diseased animals [60]. These subsequent analyses [80] were limited to micro-
scopic evaluation of the CNS to detect neuropathological features typical of, but not 
necessarily exclusive to, prion diseases including neuronal vacuolation, attendant 




6.1 Clinical signs and macroscopic lesions
The main clinical features of progressive CWD disease in adults is weight loss and 
behavioral changes that typically span weeks or months. Besides weight loss, diseased 
animals may show a wide range of behavior changes for a long time that include 
somnolence, lassitude, repetitive walking, polydipsia, and polyuria. Gradually, the 
affected cervids may exhibit ataxia, mainly in the hind limbs, head tremors, drooped 
ears, and fixed gaze, and may have difficulty in swallowing. In the end stage, they may 
show signs of sialorrhea and teeth grinding [235, 236]. The clinical signs may be subtle 
requiring that the animal keeper/observer is familiar with and has some knowledge of 
the normal behavior of the species. As a result, the disease is most commonly detected 
in emaciated cervids hunted, killed, or injured by road accidents or found dead [235].
At necropsy, severe emaciation, poor hair coat condition, megaesophagus, froth 
or watery rumen contents (often containing sand), abomasal or omasal ulcers, 
serous atrophy of bone marrow and pericardial fat, enlarged adrenal glands, muscle 
atrophy [237], and aspiration pneumonia are common findings. As the clinical signs 
and the macroscopic findings at necropsy are not pathognomonic [49], other dis-
eases must be ruled out, namely, listeriosis, meningoencephalitis, brain abscesses, 
starvation, nutritional deficiencies or severe parasitism, bluetongue disease, 
epizootic hemorrhagic disease, meningeal worms (Parelaphostrongylus tenuis), and 
locoweed intoxication [49, 235, 238].
TSEs present very specific diagnostic challenges because of their strain varia-
tion, their very long incubation period, and the lack of pathognomonic clinical 
signs. Moreover, the disease pathogenesis can range both among and within species 
due to the influence of strain, host genotype, or a combination of the two [239].
6.2 Rapid screening testing
The initial diagnosis of TSE in all species was based on passive surveillance (e.g., 
clinical presentation) and assessment via conventional histopathology and subse-
quently detection of PrPsc by IHC, both time-consuming, technically demanding, 
and expensive for large surveillance plans [77]. For that reason, the development 
of commercial rapid immunologically based screening tests (RT) for the detection 
of PrPsc in tissue homogenates allowed a large-scale active surveillance program for 
TSE in cattle and small ruminants.
These were originally developed for the detection of BSE in the cattle brain, 
and extensive formal test evaluation of a wide range of these RT was undertaken 
at Europe level [240, 241]. Mainly, there are two types of these RT kits allowing 
the purification, concentration, and detection of PrPsc from samples of tissues 
obtained from infected animals. Both assays consisted in an immuno-enzymatic 
technique: one is a sandwich format using two antibodies for the detection of the 
antigen PrPsc after proteinase K digestion (e.g., TeSeE BioRad®), and the other uses 
a PrPsc-specific ligand immobilized on the surface of the antigen-capture plate (e.g., 
HerdCheck IDEXX®). Both are suitable for the surveillance of CWD as diagnostic 
methods for the detection of the disease [77].
The limited experience in CWD so far in Europe has not allowed us to know the 
best tissue to be proposed as the most sensitive for surveillance in all circumstances. 
Sampling only the brain stem could reduce the diagnostic sensitivity for strain-
host combinations that are characterized by early lymphoid PrPsc accumulation. 
Consequently, lymphoid tissues (preferably the tonsils, retropharyngeal lymph 
nodes, and lymphoid tissues of rectal mucosa) and the brain stem at the level of 
the obex should be tested to maximize the diagnostic sensitivity in any surveillance 
program [77].
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6.3 Confirmatory testing
Like in other recognized animal TSEs, confirmation of an initial CWD “screen-
ing positive” (or “suspect”) sample can be undertaken by histopathological exami-
nation and immunodetection methods either by IHC or Western blot (WB). The 
former enables PrPsc accumulations to be assessed regarding the types of deposition 
and anatomical distribution (including cellular) location, while the latter gives 
some classification data based on the molecular mass and glycosylation profiles of 
the PrPsc [77].
Histopathologic lesions in the encephalon are similar to those described for 
ruminant TSEs: perikaryon neuronal vacuoles, microcavitation of the gray mat-
ter, astrogliosis, neuronal degeneration and loss, and PrP positively labeled prion 
deposits and plaques [242]. Duration of clinical disease does not significantly affect 
the distribution or severity of lesions, and inflammatory cell response is not appar-
ent, unless associated with intercurrent disease [49]. In clinically affected cervids, 
examination of well-fixed medulla oblongata at the level of the obex is considered 
sufficient for diagnosis of CWD [80], and sections at this level were used for CWD 
surveillance before availability of immunohistochemistry [49].
Neuropathology varies slightly between deer and elk: elk have more severe 
lesions in the thalamus and in some white matter areas. Congo red birefringent 
and PAS-positive amyloid plaques have been seen in the deer brain but not in elk 
[80]. The cerebral cortex and basal ganglia of the elk with CWD show minimal 
fine spongiform degeneration and astrogliosis with focal distribution. The spon-
giform degeneration with astrogliosis is more prominent in the thalamus where 
it forms clusters of coarse vacuoles. Fine spongiosis, often in small clusters, is 
present in the molecular layer of the cerebellum, in dorsal nuclei of the pons, and 
in the substantia gelatinosa of the spinal cord. Occasional large neurons in various 
nuclei of the pons show a vacuole [243]. Amyloid plaques are relatively common 
and can be detected on hematoxylin and eosin (HE)-stained brain sections, most 
prominently and with decreasing frequency, in white-tailed deer, mule deer, and 
elk [49]. Neuronal loss and astrogliosis are minimal except for the molecular layer 
of the cerebellum, which shows rarefaction of granule cells with no indication of 
apoptosis [243].
The PrPsc immunostaining is consistently present in the cerebral cortex, basal gan-
glia, and thalamus. In the cerebellum the immunostaining is present in both molecular 
and granule cell layers as well as in the dentate nucleus. In the pons it is widespread 
over gray structures, whereas in the spinal cord, it is generally confined to the dorsal 
part of the dorsal horns [243]. Patterns of PrPsc deposition in CWD-affected cervid 
brains include perineuronal and perivascular accumulation, extracellular plaques and 
granular deposits, and subependymal and subpial deposition [49] (Figure 5).
Recently, a different neuropathologic phenotype, characterized mainly by 
intraneuronal deposition of PrPsc and few immunostaining at the dorsal motor of 
the vagus nerve, was observed in the putative atypical CWD detected in Norwegian 
moose [31].
Deposition of PrPsc occurs widely in lymphoid tissues (Figure 5) during CWD 
incubation in the absence of histologic lesions in these tissues, resembling classical 
scrapie in small ruminants [149, 244]. Therefore, lymphoid tissues are very useful 
for diagnostic purposes and surveillance. Nevertheless, in the referred atypical 
CWD, no PrPsc was detected in lymphoid tissue [31], similar to that described in 
heterozygote ARR sheep affected with classical scrapie as well as atypical scrapie. 
In those cases, lymphoid tissues infectivity should be further studied like it was in 
atypical scrapie, demonstrating that infectivity can accumulate in lymphoid tissues 
even with no detectable PrPsc [245].
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If histopathological examination cannot be carried out due to poor state of the 
sample and/or IHC results which are not conclusive, then Western immunoblotting 
is the remaining confirmation method available. This technique relies on detergent 
extraction followed by treatment with proteinase K to digest any PrPc and detect 
only PrPsc by a specific antibody presenting bands that correspond to proteins 
within a range of molecular mass from 17 kDa (unglycosylated PrPsc) to 27 kD 
(diglycosylated PrPsc) [238].
Figure 5. 
PrPsc immunohistochemistry in CWD affected deer. (A) Perineuronal and granular deposits in neuropil 
at dorsal vagal nucleus (brainstem), X400; (B) Extracelullar plaque-like deposits (cerebral cortex), 
X200; (C) perivascular type (brainstem), X200; (D) distribution in both molecular and granular layers 
of the cerebellum, X200; (E) and (F) presence of PrPsc in several follicules in a lymph node, X100 and 
X200, respectivelly. (A–D) sections from CWD control samples kindly provided by professor Stefanie Czub 
(Canadian food inspection agency, National Center for animal diseases) in 2003; (E-F) sections from the 
CWD proficiency testing 2008 organized by the European reference laboratory for TSEs (APHA, Weybridge). 
(A-D) specific PrPsc signal was visualized with F99/97.6.1 monoclonal antibody (raised against bovine 
residues 220–225; VMRD Inc., Pullman, WA; 1:1250 dilution) StreptABC-alkaline phosphatase, new Fuchsin 
system (DAKO); (E and F) IHC with 2G11 monoclonal antibody (raised against ovine PrP peptide sequence 
146-R154-R171–182; Institute Pourquier;1:200 dilution). All tissue sections were counterstained with Mayer’s 
hematoxylin.
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WB and IHC allow a comparison of labelling patterns with antibodies that 
recognize different epitopes of the protein and help to clarify specific proteinase K 
cleavage inherent of strains type. This approach forms the basis of the discrimina-
tory testing of small ruminant isolates, to differentiate between isolates that can be 
classified as scrapie, and those that are considered BSE-like by looking at the lower 
molecular weight for the unglycosylated protein band and the ratio of the mono- 
and diglycosylated fragments, for example, between classical, atypical/Nor98, and 
CH1641 scrapie in sheep and goats and BSE and scrapie [246, 247].
The Norwegian atypical CWD (Nor-16CWD) also presented an unusual PrPsc 
electrophoretic pattern distinguishable from previous CWD cases and from known 
ruminant prion diseases in Europe, with the possible exception of sheep CH1641. 
Transmission studies in several rodent models are ongoing to clarify if this different 
phenotype could reflect the presence of a new cervid prion strain in moose from 
Norway [31].
6.4 New diagnostic methods
Regarding diagnosis in vivo, more sensitive diagnostic methods are desirable. 
Using in vitro conversion such as protein misfolding cycling amplification (PMCA) 
or real-time quaking-induced conversion assay (RT-QuIC), CWD prions are detect-
able already at a preclinical stage in specimen that can be obtained antemortem by 
noninvasive methods, such as blood, urine, feces, or saliva.
During PMCA, the normal form of PrP (PrPc) is converted into protease 
K-resistant PrP (PrPsc) using small amounts of infectious PrPsc. Continued recruit-
ment and conversion of PrPc by PrPsc are accomplished by sonication in a process 
analogous to amplification of DNA by the polymerase chain reaction (PCR). This 
amplification process enhances detection sensitivity by several orders of magnitude 
as compared to WB and has been used to confirm the presence of CWD prions in 
muscle [248] and feces [249].
In the assay referred to as real-time quaking-induced conversion (RT-QuIC) 
[250], prion seeds are thought to induce recombinant PrP to adopt a β-sheet 
structure. Thioflavin T, added to the reaction, is incorporated into the grow-
ing amyloid causing an altered spectrofluorimetric emission pattern, which is 
monitored over time.
CWD still represents a challenge in TSE research for which transmission and 
dissemination remain unchecked. The tools of diagnostic available for identifying 
infected animals have steadily progressed over time from clinical and pathological 
descriptions to antibody–antigen-dependent immunoassays and more recently 
qualitative and quantitative prion amplification techniques. These tools have 
provided a deep understanding of disease pathogenesis and transmission and 
allowed animal health technicians to monitor the expanding geographical presence 
of CWD [251].
7. Surveillance and control of CWD
7.1 Surveillance
Of further concern is the fact that CWD is the only transmissible spongiform 
encephalopathy known to be expanding both geographically and in prevalence [5].
After the confirmation in 2016 of two cases of CWD in a wild reindeer (April) 
and a wild moose (May) in Norway (the first CWD cases in Europe), this country 
intensified its surveillance program for CWD in cervids and detected a number 
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of other cases of CWD in reindeers and in moose. In the meantime, the European 
Commission (EC) requested the European Food Safety Agency (EFSA) to recom-
mend surveillance activities and, if necessary, additional animal health risk-based 
measures to prevent the introduction of the disease and the spread into/within the 
European Union (EU), specifically Estonia, Finland, Iceland, Latvia, Lithuania, 
Norway, Poland, and Sweden [252]. Based on EFSA opinion, the EC places in 
force the Commission Regulation (EU) 2017/1972, amending Annexes I and III 
of Regulation (EC) No. 999/2001 as regards a surveillance program for chronic 
wasting disease in cervids in Estonia, Finland, Latvia, Lithuania, Poland, and 
Sweden and repealing Commission Decision 2007/182/EC (which provided require-
ments for a survey on CWD in cervids which was carried out from 2007 to 2010). 
According to this new regulation, the member states (MSs), which have a wild 
and/or farmed and/or semidomesticated population of moose band/or reindeer 
(aforementioned MSs), shall carry out a 3-year monitoring program for CWD from 
1 January 2018 to 31 December 2020.
The 3-year CWD monitoring program shall cover animals over 12 months of 
age, estimated on the basis of dentition, obvious signs of maturity, or any other 
reliable information, of the following cervid species:
• Eurasian tundra reindeer (Rangifer tarandus tarandus)
• Finnish forest reindeer (Rangifer tarandus fennicus)
• Moose (Alces alces)
• Roe deer (Capreolus capreolus)
• White-tailed deer (Odocoileus virginianus)
• Red deer (Cervus elaphus)
According to some authors [252, 253], in order to avoid unbiased prevalence or 
incidence estimates and to obtain a representative set of animals, a random sampling 
is always recommended to design monitoring program. This classical approach may be 
possible to achieve for farmed cervids, but, for wildlife population, random sampling 
may not be possible to design as sampling frames are not available [252]. However, 
when disease detection is the first objective, a sampling targeting high-risk animals 
may be more efficient. That, in fact, was the case of the Norwegian monitoring pro-
gram that detected the two CWD cases through sampling of “suspect” cervids [252].
Since the aims of the proposed surveillance system were to detect disease in 
countries where CWD has not yet been detected and to estimate prevalence in areas 
where disease has been detected, the 3-year surveillance system includes a two-
stage sampling program (Commission Regulation (EU) 2017/1972):
• At the first stage, a random sampling is applied for wild/semidomesticated cer-
vids [primary sampling (PSU)] corresponding to geographical areas containing 
cervid populations, whereas for farmed cervids they will correspond to farms.
• At the second stage, a convenience sampling is applied targeting high-risk 
animals of the selected species within PSU (Figure 6).
To date, according to Commission Regulation (EU) 2017/1972, member states 
shall carry out additional monitoring for TSEs in cervids based on a risk assess-
ment which may take into account the detection of a TSE in cervids in the same or 
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neighboring regions. Efforts to prevent the introduction of CWD should consider 
whether prior surveillance data are sufficient to assure that the disease has not 
already spread into the area of interest.
Based on the main provisions in the TSE regulation currently applicable to 
CWD, TSE-positive cases in cervids must be notified to the commission and the 
member states (Article 11 of Regulation (EC) No. 999/2001), and all parts of the 
body of a cervid positive for TSE must be sent to disposal as category 1 materi-
als in accordance with the Animal By-Product Regulation 10 (Article 13.1. (a) of 
Regulation (EC) No. 999/2001).
7.2 TSE control
As it was previously referred (see Section 4), CWD is a very contagious form of 
TSE. Therefore, control in captive cervids is not easy and even more in the wildlife. 
According to Uehlinger and colleagues [254], the combination of direct and environ-
mental transmission of CWD prions; the persistence of environmental infectious prion 
for at least for 2.5 years [255]; the absence of a rapid, practical, and reliable antemortem 
field tests for detecting preclinical CWD; and the nonavailability of licensed vaccines nor 
therapies together with the impossibility of quarantine suspicions populations in wild 
cervids make the control of this disease in wild populations very difficult.
The management of CWD in affected populations is a proven difficult task, 
based on population reduction in the case of wild deer or in quarantine and depop-
ulation in commercially reared animals.
Measures to control the spread of the disease will depend on whether we are 
dealing with commercially exploited herds, confined to demarcated areas, or with 
wild populations of deer. In the first case, and similar to other infectious diseases and 
other livestock, programs to detect and eliminate positive animals may be used [94].
This task is not easy, however, as a shown by a 2018 study conducted on a private 
farm in Colorado where the use of disease control management through rectal 
biopsy diagnosis was not able to prevent the increase in prevalence suggesting the 
need to refine management criteria or antemortem diagnostic methods [5].
Thus, the science available to inform effective CWD management and control 
strategies remains relatively incomplete as it was concluded by different studies 
[254, 256] during their review on CWD control in North America. Nevertheless, 
it may be stated that approaches for CWD management generally fall into three 
categories in order to prevent the introduction of the disease and its spread [252]:
a. Prevention of entry in free regions (where CWD is assumed absent or is not 
believed to occur)
b. Containment procedures of a CWD focus to avoid disease spread
c. Control/suppression in an affected herd or population
Regarding preventive and containment strategies, it was referred that these 
measures tend to focus on regulations (e.g., bans on movements of live animals, 
carcasses, or specified risk materials) and efforts to prevent the introduction of 
CWD should consider whether prior surveillance data are sufficient to assure that 
the disease has not already spread into the area of interest [252].
Haley and collaborators [94] suggest that outer mechanisms of disease 
control could be useful like the development of simple antemortem test to use 
prior to animal movements among farms, the breeding for resistant genotypes, 
the installation of effective fences to prevent transmission between commercial 
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and wild populations, and equipment cleaning and quarantine prior to animal 
introduction.
Free-ranging deer population reduction is empirically effective in reducing a 
disease with direct contact transmission, but several studies have shown that in the 
case of CWD, the results are below expected [94, 257].
Capturing, testing, and recapturing positive free-ranging mule deer did not 
reduce prevalence in the female population [258].
Concerning the prevention of entry in free regions, according to Regulation 
(EC) No. 999/2001, in the EU, the feeding to cervids of proteins derived from 
animals is prohibited, with the exception of milk and milk products, eggs and egg 
products, hydrolyzed proteins from nonruminants or from ruminant hides and 
skins, and gelatine and collagen from nonruminants (Article 7 and Annex IV). Also, 
at import into the EU, an attestation is required for meat and meat products from 
wild and farmed cervids coming from the USA or Canada (Chapter F of Annex IX), 
confirming that the products:
• Exclude the offal and spinal cord
• Are derived from animals tested for CWD with negative results
• Are derived from animals which do not come from a herd (for farmed animals) 
or a region (for wild animals) where CWD has been confirmed or officially 
suspected
As a result of the detection of the first case in Norway, in Europe, in addition 
to the permanent measures as described in the aforementioned regulation, the 
Commission Implementing Decision (EU) 2016/1918 enforced temporary safe-
guard measures in relation to CWD (until December 31, 2017). According to this 
Figure 6. 
Surveillance program for CWD in cervids. Schematic presentation of two-stage sampling approach of the 
3-year surveillance programme for CWD in cervids in Estonia, Finland, Latvia, Lithuania, Poland and 
Sweden in cervids defined on commission regulation (EU) 2017/1972.
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decision, the movement of live cervids from Norway into the European Union 
was prohibited with several derogations permitting its movements under certain 
circumstances (e.g., movements of live cervids from Norway to Sweden or Finland 
for direct slaughter; movements of live reindeer for seasonal grazing from Norway 
to some listed areas in Sweden and Finland).
According to the European Food Safety Agency [252], the derogations that lay 
down in this decision present a risk of introduction of CWD into the EU, since 
it was concluded that the most likely pathway of introduction of CWD into the 
EU is the movement of live cervids, either by deliberate transportation or by the 
movement of wild animals across the border of Norway to Sweden or Finland. 
Additionally, these authors present other measures to reduce the probability of 
introduction of CWD into the EU, namely, the use of natural cervid urine lures and 
awareness campaigns targeting both local Norwegian hunters and hunters visiting 
Norway from (and returning to) other countries regarding the personal protective 
equipment (PPE), disinfection, the safe dressing of carcasses, and the appropriate 
disposal of carcass trimmings.
In general, according to several authors [252, 254, 256], other measures can be 
implemented in order to contain and/or to control/suppress CWD in a region or 
country where the disease is present. Some of those measures may include:
• Reducing environmental contamination (e.g., interdict the use of dead cervids 
to feed wildlife nor to use as baits for hunting, unless they have been tested 
negative, prior to use).
• Reduction of animal-to-animal contact (e.g., ban artificial feeding, lick blocks 
or other congregating management procedures).
• Decrease population densities by definition of strategic plan for hunting 
management policies (e.g. increasing harvest permits and/or hunting season) 
and culling practices.
Regarding the last measure (decrease population), Uehlinger and colleagues 
[254] alert that:
• To date, the evidence is unclear that increased nonselective culling pressure has 
a beneficial effect on the spread or prevalence of CWD.
• Culling of wildlife is often unpopular. For that reason, any control program 
that includes culling of animals must take into account the public acceptance 
and hunters’ attitudes and behaviors.
Since dispersion of infected deer may not be limited by political boundaries, 
regional and interstate/interprovincial cooperation and collaboration will be an 
important part of any successful management strategy. Also, it is always important 
to evaluate the costs in order to understand the feasibility of the control strategy 
proposals (when developing any intervention program) [254].
This review gathers known and recent features of this progressive and fatal 
neurodegenerative disease affecting cervid species, contributing for chronic wast-
ing disease awareness among scientific community and stakeholders. Conscious 
that research in this field has a long way to go to answer many of the questions that 
remain open, we believe that this review will contribute to the understanding of the 
occurrence of prion diseases in wildlife.
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